lansoprazole brands

6 registered brands containing lansoprazole in Zimbabwe.

Lansoprazole

PubChem CID 3883

Molecular formula: C16H14F3N3O2S

As a PPI, lansoprazole is a prodrug and requires protonation via an acidic environment to become activated. Once protonated, lansoprazole is able to react with cysteine residues, specifically Cys813 and Cys321, on parietal H+,K+-ATPase resulting in stable disulfides. PPI's in general are able to provide prolonged inhibition of acid secretion due to their ability to bind covalently to their targets. Lansoprazole is a selective and irreversible proton pump inhibitor. In the acidic environment of the gastric parietal cell, lansoprazole is converted to active sulphenamide derivatives that bind to the sulfhydryl group of (H+, K+)-adenosine triphosphatase ((H+,K+)-ATPase), also known as the proton pump (H+,K+)-ATPase catalyzes the final step in the gastric acid secretion pathway. Lansoprazole's inhibition of (H+,K+)-ATPase results in inhibition of both centrally and peripherally mediated gastric acid secretion. The inhibitory effect is dose-related. Lansoprazole inhibits both basal and stimulated gastric acid secretion regardless of the stimulus.

Source: PubChem (NCBI) ยท compound 3883

Product Manufacturer Status Country
HELIGO 500
TABLET, COATED; ORAL
Intas Pharmaceuticals PRESCRIPTION PREPARATIONS 9TH SCHEDULE, (P.P.) Zimbabwe
LAN-30
TABLET, COATED; ORAL
Intas Pharmaceuticals PHARMACIST INITIATED MEDICINES, (P.I.M.) Zimbabwe
LANSA 15
CAPSULE; ORAL
Inventia Healthcare PHARMACIST INITIATED MEDICINES, (P.I.M.) Zimbabwe
LANSA 30
CAPSULE; ORAL
Inventia Healthcare PHARMACIST INITIATED MEDICINES, (P.I.M.) Zimbabwe
RELANSO
CAPSULE; ORAL
Inventia Healthcare Pvt Ltd, F1-f1/1-f75/1, Additional Ambernath Midc PHARMACIST INITIATED MEDICINES, (P.I.M.) Zimbabwe
RELANSO
CAPSULE; ORAL
Inventia Healthcare Pvt Ltd, F1-f1/1-f75/1, Additional Ambernath Midc PHARMACIST INITIATED MEDICINES, (P.I.M.) Zimbabwe